Total Mesometrial Resection With (Neo)Adjuvant Chemotherapy in Locally Advanced Cervical Cancer: A Tumor Response Score

• Published in: Anticancer research Vol. 41; no. 7; pp. 3543 - 3560
• Main Authors: KIESEL, MATTHIAS, SAUER, STEPHANIE, LÖB, SANJA, HERBERT, SASKIA L., WÖCKEL, ACHIM, WULFF, CHRISTINE
• Format: Journal Article
• Language: English
• Published: Athens International Institute of Anticancer Research 01-07-2021
• Subjects: Antigens; Cancer; Cervical cancer; Chemoradiotherapy; Chemotherapy; Cisplatin; Diameters; Ifosfamide; Lymph nodes; Magnetic resonance imaging; Metastases; Paclitaxel; Patients; Squamous cell carcinoma; Tumors; Uterus
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.15142

Background/Aim: There is a lack of data concerning the surgical treatment of locally advanced squamous cell carcinoma of the uterine cervix (LACC) with neoadjuvant and adjuvant chemotherapy (NACT, ACT) as well as total mesometrial resection (TMMR). The aim of the study was to present a novel approach for treating LACC using a tumor response score for NACT. Patients and Methods: A total of 12 patients with LACC were treated with NACT [cisplatin, ifosfamide, paclitaxel (TIP)], TMMR and ACT containing TIP. To measure the response during NACT, we scored i) the maximum tumor diameter (maxTD) in gynecological examination, ii) the MRI for radiologic maxTD, iii) the tumor volume and iv) the squamous cell carcinoma antigen before and after two applications of TIP. Results: TIP reduced all score-parameters in 10 of 12 patients (p<0.005). We found a possible reduction of lymph node metastasis in 72.7%. The proposed score detected sufficient and insufficient tumor response. Conclusion: TIP followed by TMMR with ACT could be a possibility for patients denying radiochemotherapy. The tumor response score can detect patients with inadequate benefit from NACT.